At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 20 enrolled
Drug / intervention
ACTH (Acthar) Geldrug
Likely dose
ACTH (Acthar) Gel 80 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
In Brief
A Phase 3 clinical trial evaluating ACTH (Acthar) Gel for Progressive IgA Nephropathy and Proteinuria. Completed, enrolled 20 participants across 4 sites.
Detailed Summary
This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgressive IgA Nephropathy, Proteinuria
CountriesUnited States
CollaboratorsMallinckrodt
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartMar 2015
Primary CompletionJun 2018
TodayJul 2026
First PostedNov 5, 2014
Enrollment StartMar 1, 2015
Primary CompletionJun 30, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.7 years ago
Interventions
ACTH (Acthar) Geldrug
Injected dose of 80 units subcutaneously twice weekly for 6 months.